A61P 27/00
Drugs for disorders of the senses
A61P27/00 (Drugs for disorders of the senses) appears on 24,757 US grants and 38,379 published applications in this corpus.
Search patents in A61P- Granted patents
- 24,757
- Published applications
- 38,379
- Assignees
- 8,046
- Inventors
- 49,327
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 2 | 0 |
| 1978 | 14 | 0 |
| 1979 | 10 | 0 |
| 1980 | 15 | 0 |
| 1981 | 11 | 0 |
| 1982 | 11 | 0 |
| 1983 | 10 | 0 |
| 1984 | 22 | 0 |
| 1985 | 23 | 0 |
| 1986 | 19 | 0 |
| 1987 | 23 | 0 |
| 1988 | 45 | 0 |
| 1989 | 57 | 0 |
| 1990 | 66 | 0 |
| 1991 | 76 | 0 |
| 1992 | 78 | 0 |
| 1993 | 85 | 0 |
| 1994 | 101 | 0 |
| 1995 | 141 | 0 |
| 1996 | 146 | 0 |
| 1997 | 185 | 0 |
| 1998 | 223 | 0 |
| 1999 | 280 | 0 |
| 2000 | 315 | 0 |
| 2001 | 416 | 106 |
| 2002 | 510 | 664 |
| 2003 | 478 | 1139 |
| 2004 | 409 | 1411 |
| 2005 | 410 | 1457 |
| 2006 | 563 | 1566 |
| 2007 | 593 | 1568 |
| 2008 | 660 | 1971 |
| 2009 | 779 | 2272 |
| 2010 | 1171 | 2451 |
| 2011 | 1230 | 2343 |
| 2012 | 1487 | 2256 |
| 2013 | 1676 | 1872 |
| 2014 | 1657 | 1880 |
| 2015 | 1455 | 1690 |
| 2016 | 1266 | 1770 |
| 2017 | 1258 | 1589 |
| 2018 | 1174 | 1530 |
| 2019 | 1059 | 1444 |
| 2020 | 1005 | 1354 |
| 2021 | 883 | 1275 |
| 2022 | 681 | 1167 |
| 2023 | 563 | 1054 |
| 2024 | 559 | 1060 |
| 2025 | 528 | 848 |
| 2026 | 327 | 642 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Polysaccharide encapsulated oxygen nanobubbles6 Oct 2026US 12,751,927 B2The Board of Trustees of the University of Illinois
- Topical ocular delivery of cromakalim6 Oct 2026US 12,751,939 B2Mayo Foundtation for Medical Education and Research
- OPA1 antisense oligomers for treatment of conditions and diseases6 Oct 2026US 12,753,408 B2Stoke Therapeutics, Inc.
- Compositions and methods for treating age-related macular degeneration29 Sep 2026US 12,746,246 B2Tufts Medical Center, Inc.
- Blood-brain barrier permeable heteroduplex nucleic acid29 Sep 2026US 12,746,253 B2National University Corporation Tokyo Medical and Dental University
- Sulfurized imidazoles in ophthalmic formulations8 Oct 2026US 2026/0306431 A1Geneiii Biotech Company Ltd.
- Sulfurized imidazoles in ophthalmic formulations8 Oct 2026US 2026/0306457 A1Geneiii Biotech Company Ltd.
- Composition for removing and inhibiting senescent cells, and uses thereof8 Oct 2026US 2026/0306460 A1Lifeceutix Co., Ltd.
- Novel glycan compounds for age-related macular degeneration8 Oct 2026US 2026/0306530 A1The Regents of the University of California
- Retinal pigment epithelium cell therapy8 Oct 2026US 2026/0306548 A1The Regents of the University of California
Most cited
By later US patents
- Drug delivery devices, kits and methods therefor1,366US 8,521,273 B22013
- Controlled-release biocompatible ocular drug delivery implant devices and methods780US 6,331,313 B1Oculex Pharmaceticals, Inc. · 2001
- Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation733US 9,101,621 B2Celgene Corporation · 2015
- Regulation of endogenous gene expression in cells using zinc finger proteins648US 6,534,261 B1Sangamo BioSciences, Inc. · 2003
- Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation489US 8,865,406 B2Massachusetts Institute of Technology · 2014